JBM (Healthcare) (HKG:2161) recorded a 53% rise in attributable profit for the six months ended Sept. 30 to HK$95.9 million from HK$62.5 million in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.

Earnings per share were HK$0.1163 in the fiscal first half, up from HK$0.0687 in the corresponding period of fiscal year 2023.

The Chinese medicine distributor's revenue rose by 22% to HK$399 million in the interim period from HK$326.8 million a year prior.

The firm declared an interim dividend of HK$0.055 per share for the half year, payable Jan. 15, 2025, to shareholders of record on Dec. 20, 2024.